End Stage Renal Disease. Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention group: Cap Omega-3 1000mg 3capsule per day for 6 months manufactured by Zahravi company. Intervention 2: Control group: Cap placebo for 6 months manufactured by Zahravi co
Treatment - Drugs
Placebo
Intervention group: Cap Omega-3 1000mg 3capsule per day for 6 months manufactured by Zahravi company
Control group: Cap placebo for 6 months manufactured by Zahravi company
Sponsors
Vice Chancellor for Research, Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: at least 18 years old; hemodialysis for at least 3 months; consent for cooperation; without usage of omega-3 during past 3 months Exclusion criteria: history of steatorrhea; malignancy; abnormal coagulation profile; need for anticoagulation therapy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Q-CRP level. Timepoint: At begining and after 6 months. Method of measurement: ELISA kit, mg/dL.;Serum TNF-a level. Timepoint: At begining and after 6 months. Method of measurement: ELISA kit, mg/dL. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Yaser Salehi
Isfahan University of Medical Sciences
Outcome results
None listed